Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4730686 | 0.84 | POLB (0.38) | — | |
| SCHEMBL4727344 | 0.84 | POLB (0.38) | — | |
| SCHEMBL10203868 | 0.82 | LMNA (0.39) | LMNASMN1; SMN2ALDH1A1PIK3CAPIK3CB | |
| SCHEMBL4730445 | 0.81 | CYP1A2 (0.40) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4730736 | 0.79 | MEN1 (0.38) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1632220 | 0.78 | FFAR3 (0.30) | — | |
| SCHEMBL4729530 | 0.78 | CYP3A4 (0.32) | — | |
| SCHEMBL4728395 | 0.78 | CYP3A4 (0.32) | — | |
| SCHEMBL4728514 | 0.77 | USP2 (0.38) | ALDH1A1 | |
| SCHEMBL4739332 | 0.77 | LMNA (0.35) | LMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | HAVCR2, SLC10A1, HDGF | LMNA 3347/4885SMN1; SMN2 4775/4885ALDH1A1 2379/4885 |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | LMNA 3671/4885SMN1; SMN2 4692/4885ALDH1A1 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.